Gastrointestinal effects (overall)
The set of digestive complaints recorded in REDEFINE-1 with CagriSema: they occurred in 79.6% of participants compared with 39.9% on placebo. Most were mild or moderate and short-lived.
Institutional endorsement by Clínica Evolution
This entry is for information. Your case requires an individual medical assessment.